Notice Concerning Status of Acquisition of the Company's Own Shares

(Acquisition of Company's own shares pursuant to the provisions of the Articles of Incorporation based on the provisions of Article 165, Item 2 of the Corporate Law)

KISSEI PHARMACEUTICAL CO., LTD. (the "Company") announces status of acquisition of its own shares pursuant to Article 156 of the Corporate Law after applying the provisions of Article 165, Item 3 of the Law, which was announced on May 8, 2023, as follows.

1.　Type of shares acquired: Common shares of the Company
2.　Total number of shares acquired: 103,700 shares
3.　Total amount of shares acquired: 303,090,800 yen
4.　Period of acquisition: Started on June 1, 2023 and ended on June 30, 2023 (based on contract date)
5.　Acquisition method: Market purchases on the Tokyo Stock Exchange based on a discretionary trading contract regarding acquisition of own shares

(Reference)

1.　Details of the resolution at the meeting of Board of Directors held on May 8, 2023

1) Type of shares to be acquired: Common shares of the Company
2) Total number of shares to be acquired: Up to 2,000,000 shares

(Percentage of total number of issued shares (excluding treasury shares) : 4.34%)

3) Total acquisition cost: 6 billion yen (maximum)
4) Acquisition period: From May 10, 2023 to March 29, 2024
5) Acquisition method: Market purchases on the Tokyo Stock Exchange

1.Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
2.Market purchases based on a discretionary trading contract regarding acquisition of own shares

2.　Cumulative number and value of own shares acquired so far based on the above resolution at the Board of Directors meeting (As of June 30, 2023)

1) Total number of shares acquired: 192,400 shares
2) Total amount of shares acquired: 556,874,300 yen